E
EDWARDS LIFESCIENCES CORP
NYSE: EW (Edwards Lifesciences Corporatio)
Last update: 2 hours ago81.44
0.45 (0.56%)
| Previous Close | 80.99 |
| Open | 80.95 |
| Volume | 4,648,444 |
| Avg. Volume (3M) | 4,821,001 |
| Market Cap | 47,300,354,048 |
| Price / Earnings (TTM) | 44.99 |
| Price / Earnings (Forward) | 27.25 |
| Price / Sales | 7.82 |
| Price / Book | 4.52 |
| 52 Weeks Range | |
| Earnings Date | 23 Apr 2026 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bullish |
AIStockmoo Score
-0.8
| Analyst Consensus | 5.0 |
| Insider Activity | -4.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -0.5 |
| Average | -0.80 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ninety One Uk Ltd | 31 Dec 2025 | 7,734,946 |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt | 31 Dec 2025 | 7,732,010 |
| Brown Advisory Inc | 31 Dec 2025 | 7,332,126 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 103.00 (BTIG, 26.47%) | Buy |
| Median | 100.00 (22.79%) | |
| Low | 89.00 (Truist Securities, 9.28%) | Hold |
| Average | 97.40 (19.60%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 79.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 11 Feb 2026 | 103.00 (26.47%) | Buy | 79.33 |
| Goldman Sachs | 11 Feb 2026 | 95.00 (16.65%) | Buy | 79.33 |
| Piper Sandler | 11 Feb 2026 | 100.00 (22.79%) | Buy | 79.33 |
| Truist Securities | 11 Feb 2026 | 89.00 (9.28%) | Hold | 79.33 |
| Wells Fargo | 11 Feb 2026 | 100.00 (22.79%) | Buy | 79.33 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ULLEM SCOTT B. | - | 79.15 | -13,000 | -1,028,950 |
| Aggregate Net Quantity | -13,000 | |||
| Aggregate Net Value ($) | -1,028,950 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 79.15 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ULLEM SCOTT B. | Officer | 09 Apr 2026 | Automatic sell (-) | 13,000 | 79.15 | 1,028,950 |
| ULLEM SCOTT B. | Officer | 09 Apr 2026 | Option execute | 13,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026 |
| 02 Feb 2026 | Announcement | Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |